CD19 and plasma cell myeloma: Indeed, CAR-iNKT cells have already been investigated against various malignancies such as B-cell lymphoma, neuroblastoma and myeloma.26–29 Rotolo et al published a comprehensive study showing the potential of CAR-iNKT cells directed against CD19.